



STATEMENT

Faes Farma strengthens its presence in Mexico setting up a joint-venture with Mexico´s first laboratory.

MIT Farma was set up today in Mexico DF with an equal holding between Faes Farma and a company belonging to the group of shareholders of Laboratorios Senosian, Mexico´s first Laboratory.

L. Senosiaín has been, with great success, our licensee in Mexico for over 15 years for hidrosmine, a venous vasoprotectant researched by Faes Farma.

The excellent relations between both companies during this period, along with shared business views and values, have allowed us to take this step which opens a valuable opportunity for both laboratories. We are convinced that L. Senosiaín is the best possible partner for Faes Farma in the Mexican market.

Faes Farma will provide its innovative and differentiated products for their commercialization in the Mexican market through the joint-venture, and L. Senosiaín will contribute with its knowledge of the local market, which has allowed them to become the leader Mexican pharmaceutical company and the 5th laboratory in Mexico, including multinationals.

The joint company, MIT Farma, will market a second brand for Mexico of the antihistaminic bilastine (in addition to the one already commercialized by Pfizer), a second brand of hidrosmine, other original products from Faes Farma´s portfolio and innovative products which are, at present, being developed by Faes Farma.



Faes Farma enters a market, the Mexican, with a population over 110 million and a pharmaceutical market value equivalent, at present, to 75% of the Spanish market value, with the difference that the Mexican market is clearly growing.

With this agreement, Faes Farma takes a decisive step in its strategy to achieve a solid regional presence throughout all Latin America.

October 28th 2013.